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Cognitive impairment and emotional disturbances in Alzheimer's disease (AD) result from the degeneration of synapses and neuronal death in
the limbic system and associated regions of the cerebral cortex. An alteration in the proteolytic processing of the amyloid precursor protein (APP)
results in increased production and accumulation of amyloid β-peptide (Aβ) in the brain. Aβ can render neurons vulnerable to excitotoxicity and
apoptosis by disruption of cellular Ca2+ homeostasis and neurotoxic factors including reactive oxygen species (ROS), nitric oxide (NO), and
cytokines. Many lines of evidence have suggested that transient receptor potential (TRP) channels consisting of six main subfamilies termed the
TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), and TRPA (ankyrin) are involved in Ca2+
homeostasis disruption. Thus, emerging evidence of the pathophysiological role of TRP channels has yielded promising candidates for molecular
entities mediating Ca2+ homeostasis disruption in AD. In this review, we focus on the TRP channels in AD and highlight some TRP “suspects” for
which a role in AD can be anticipated. An understanding of the involvement of TRP channels in AD may lead to the development of new target
therapies.
© 2007 Elsevier B.V. All rights reserved.Keywords: TRP; AD; Aβ; ROS; Ca2+ homeostasis disruption1. Introduction
Alzheimer's disease (AD) is a form of dementia in which
patients show neurodegeneration, complete loss of cognitive
abilities and prematurely die. Central to the neurodegenerative
process is the inability of neurons to properly regulate
intracellular Ca2+ levels ([Ca2+]i) [1]. In AD, correlations
between the pathological hallmarks of AD (amyloid plaques
and neurofibrillary tangles) and perturbed cellular Ca2+ home-
ostasis have been established in studies of patients, and in
animal and cell culture models of AD [2]. Specifically,
increased levels of amyloid β-peptide (Aβ) induce neurotoxic
factors including reactive oxygen species (ROS) and cytokines,⁎ Corresponding author. Tel.: +81 75 383 2793; fax: +81 75 383 2765.
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doi:10.1016/j.bbadis.2007.03.006which impair cellular Ca2+ homeostasis and render neurons
vulnerable to apoptosis and excitotoxicity [3]. Studies of
the effects of mutations in the amyloid-β precursor protein
(APP) and presenilin (PS) 1 and 2 on neuronal plasticity and
survival have provided insights into the molecular cascades
that result in synaptic dysfunction and neuronal degeneration
in AD [4]. PS mutations perturb Ca2+ homeostasis that sen-
sitizes neurons to apoptosis and excitotoxicity; links between
aberrant Ca2+ regulation and altered APP processing are
emerging [5].
Neuronal toxicity is not simply attributable to the increase in
[Ca2+]i. In fact, treatment with α-amino-3-hydroxy-5-methyl-4-
isoxazoleprpionate (AMPA) or with KCl increases [Ca2+]i up
to 1–2 μM in cortical neurons without showing toxicity,
while the equivalent [Ca2+]i increase induced by Ca
2+ influx
specifically through the N-methyl-D-aspartate (NMDA) recep-
tors induces cell injury, suggesting that the identity of the Ca2+
Fig. 1. Speculated involvement of neuronal TRP channels in AD. Aβ activates
mitochondrial production of ROS, which is released into the cytosol. ROS can
activate TRPM2 and TRPM7, and consequent [Ca2+]i increases induce NO
production. NO and ROS further combine to form the highly reactive species
peroxynitrite (ONOO−). ONOO− triggers Ca2+ influx via TRPM7. Microglia
and astrocytes activated by Aβ produce TNFα, which induces TRPM2
activation and NO, which selectively modifies Cys553 and Cys558 residues to
activate TRPC5. Ca2+ influx via nitrosylated TRPC5 mediates Ca2+-dependent
NO production by neuronal NOS. It must be noted that the neuroinflammatory
process triggered by Aβ plays a central role in neurodegenerative process in AD.
This inflammatory process is driven by activated-microglia and astrocytes that
produce inflammatory molecules. Several inflammatory molecules activate
TRPV1.
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death [6]. It is also important to note that decreasing [Ca2+]i is
toxic in some neurons, while a modest increase in [Ca2+]i is
neuroprotective. These results paradoxically suggest that Ca2+
has not only deleterious but also protective effects on the
neuronal cell [6,7].
The transient receptor potential (TRP) gene was discovered
originally in Drosophila, where mutants for the gene showed
impaired vision due to the lack of a specific cation Ca2+ influx
pathway into photoreceptor cells [8]. TRP and its homologues
constitute a large and diverse family of channel proteins that are
expressed in many tissues and cell types in both vertebrates and
invertebrates [9,10]. Mammalian TRPs are plasma membrane
cation channels that have diverse physiological functions
[11–13]. The TRP superfamily can be classified into three
large subfamilies including canonical (TRPC), melastatin
(TRPM), and vanilloid (TRPV) channels, and three other
small subfamilies such as polycystin (TRPP). The TRPC sub-
family consists of seven homologues, which are receptor-
operated cation channels that play an essential role in intra-
cellular Ca2+ homeostasis. Ca2+ signaling is initiated by
neurotransmitters (e.g., agonists that activate G proteins) via
the stimulation of cell membrane receptors linked to phospho-
lipase C (PLC) activation, which leads to production of inositol
1,4,5-trisphosphate (IP3) and diacylglycerol (DG). The receptor
stimulation eventually induces a biphasic Ca2+ signal, which
is composed of an initial Ca2+ release from the endoplasmic
reticulum (ER) followed by a sustained and/or oscillatory
[Ca2+]i increase due to Ca
2+ influx across the plasma mem-
brane. Different modes of receptor-operated Ca2+ entry include
store-operated Ca2+ entry (SOC) or capacitative Ca2+ entry
(CCE), resulting from the depletion of intracellular Ca2+ stores
[14–16], as well as Ca2+ entry activated in a Ca2+ depletion-
independent manner [17–19]. In the brain, it is generally
accepted that TRPC1 channels work as a component of SOC,
whereas TRPC6 channels are involved in receptor-operated
Ca2+ entry, which can be activated independently of Ca2+
depletion [14–16]. TRPC3 channels that form receptor-operated
Ca2+ entry are highly enriched in neurons of the central nervous
system (CNS) [20]. TRPC4 channels, detected in the brain of
embryonic rats, contribute to receptor-operated Ca2+ entry [21].
Recent reports have suggested that TRPC5 channels, predomi-
nantly expressed in growth cones and early synapses in young
rat hippocampal neurons, participate in receptor-operated Ca2+
entry [22–24]. Recently, evidence has been provided for the
localization of a number of Ca2+ signaling proteins within
caveolar lipid raft domains in the plasma membrane [25,26]. In
particular, TRPC1 and TRPC3 are associated with caveolin-1,
and are assembled in a protein complex with key Ca2+
signaling proteins [27]. Ehehalt et al., have reported that lipid
rafts are critically involved in regulating Aβ production [28].
It can be surmised that TRPC channels and lipid rafts con-
tribute to Aβ regulation. The TRPM subfamily includes eight
mammalian homologues. In particular, TRPM2 and TRPM7
represent a Ca2+-permeable, non-selective cation channel ac-
tivated by ROS [29,30]. TRPM2 and TRPM7 are also involved
in oxidative stress-induced cell death [30]. The TRPV sub-family, composed of six homologues, is known to participate in
nociception, mechano-sensing, osmolarity-sensing, and thermo-
sensing [13]. TRPV1 is a modestly Ca2+-selective channel
gated by capsaicin, acidosis, and endogenous ligands, such
as anandamide [31,32]. Interestingly, TRPM2, TRPM7, and
TRPV1 have been reported to play pathological roles in the brain
[29,31].
Thus, accumulated evidence suggests that TRP channels play
prominent roles in neuronal Ca2+ signaling. In addition, ROS
involved in various pathological conditions leads to TRP
channel activation. However, many pathological aspects of
TRPs, particularly in AD, are still very unclear. Therefore, this
review will seek the correlation between AD and TRP channels
(Fig. 1).
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Ca2+ is essential for neuronal development, synaptic
transmission and plasticity, and the regulation of various
metabolic pathways in neurons [33]. Accumulating evidence
suggests that failure of Ca2+ homeostasis plays a critical role in
the neuropathology of AD. One of the postulated mechanisms of
Aβ toxicity seems to involve a disturbance of Ca2+ homeostasis
accompanied by enhanced vulnerability to excitotoxic stimuli
[1,2]. This neurotoxicity activates PLC and produces IP3, which
in turn stimulates intracellular Ca2+ stores [34] and also activates
NMDA receptors and VDCC [35,36]. In fact, both the direct
neurotoxicity of Aβ and the enhanced vulnerability
to excitotoxicity were attenuated when cells were incubated in
Ca2+-free medium, suggesting the involvement of Ca2+ influx in
this process [37].Moreover, the pathogenic mutations in PSs and
APP responsible for the early onset of familial AD have been
suggested to participate in the perturbation of cellular Ca2+
homeostasis [4,5]. FAD-linked mutant PS1 or PS2 may impair
CCE and SOC currents. Interestingly, Yoo et al. provided
evidence that inhibition of CCE selectively increases the amy-
loidogenic Aβ peptide (Aβ42) [38]. Hence, it is likely that re-
duced CCE is an early cellular event leading to Aβ42 generation
associated with FAD mutant PSs. Other reports have described
that Ca2+ released from the ER and mitochondria participates
in the pathogenesis of neuronal degeneration [39,40]. In
contrast, a study by Chen et al. has demonstrated that Ca2+
has both stimulatory and inhibitory roles in the process of cell
death [6]. This study represents the important finding of
increased [Ca2+]i resulting in neuronal cell protection (Table 1).
Alterations in Ca2+ homeostasis contribute to neuronal
apoptosis and excitotoxicity, and are linked to AD, suggesting
the potential benefits of preventative and therapeutic strategies
that stabilize cellular Ca2+ homeostasis. Many studies have
shown that [Ca2+]i is elevated by enhancing Ca
2+ influx from
voltage-dependent or voltage-independent Ca2+ channels, or by
stimulating Ca2+ release from the ER. Recently, Tu et al. [41]
have demonstrated that PS form ER Ca2+ leak channels, and the
function is disrupted by familial AD-linked mutation. Com-
pared to the general pathophysiological importance of Ca2+Table 1
TRP channels expressed in brain [65,141–144]
Subfamily Distribution in brain Proposed
TRPC1 Cerebrum, cerebellum, forebrain, hippocampus Store-ope
TRPC3 Cerebrum, cerebellum, forebrain, hippocampus Receptor-
TRPC4 Cerebrum, cerebellum, forebrain, hippocampus Receptor-
TRPC5 Cerebrum, cerebellum, forebrain, hippocampus,
hindbrain
Receptor-
TRPC6 Cerebellum, cerebrum, forebrain, hippocampus Diacylgly
TRPM2 Cerebrum, cerebellum, forebrain, hippocampus Reactive
dinucleoti
TRPM7 Cerebrum, cerebellum, forebrain, hippocampus Reactive
TRPV1 Cerebrum, hippocampus, hindbrain Capsaicin
Expression of TRPC1, TRPC3, TRPC4, TRPC5 and TRPC6, TRPM2, TRPM7 and
reviewed in this article were described in the list.influx, Ca2+ channels specifically involved in AD are poorly
understood. In this section, we review the role of TRPs as Ca2+-
permeable channels in mediating the neuroprotective and
neurodegenerative effects of Ca2+.
2.1. Neuroprotective role of TRPC1
TRPC1 is abundantly expressed in the brain. Recently,
TRPC1 channels have been shown to play pivotal roles in
neurodegeneration induced by neurotoxin, 1-methyl-4-phenyl-
pyridinium ion [42]. Bollimuntha et al. have demonstrated that
TRPC1 channels are expressed in human neuroblastoma (SH-
SY5Y) cells, which have been employed extensively in studies
of neurotransmitter release, neuronal apoptosis, neurodegenera-
tion, and Ca2+ homeostasis [42]. In this study, SH-SY5Y cells
treated with neurotoxin show significant reduction in TRPC1
protein levels, and overexpression of TRPC1 protects SH-
SY5Y cells against neurotoxin-induced apoptosis. Importantly,
activation of TRPC1 by thapsigargin or carbachol decreases
neurotoxicity. Hence, increased cell viability is dependent on
the activation of TRPC1, and its protection is partially
dependent on external Ca2+, suggestive of the neuroprotective
effect of Ca2+ influx.
As described above, TRPC1 has been suggested to function
as SOC. A recent investigation by Kim et al. has demonstrated
that, in SH-SY5Y cells, CCE is involved in regulating the
release of the soluble form of non-amyloidogenic APP (sAPP)
mediated by muscarinic acetylcholine receptor (mAChR)
activation [43]. They have speculated that augmentation or
induction of CCE leads to neuroprotection and a reduction in
Aβ generation. In support of this speculation, Yoo et al. have
reported that inhibition of CCE by SKF96365 induces an
increase in the expression of the toxic peptide, Aβ42, that is
associated with the increase in the expression of mutant PS1
[38]. These results suggest that the functional reduction in CCE
may be a causative element in AD. It has been reported that
TRPC3 and TRPC5 are also expressed in SH-SY5Y cells [42].
However, it remains to be uncovered which TRP subtypes are
indeed important in mAChR-mediated CCE and sAPP release
in SH-SY5Y cells.major regulation Possible function
rated Neuroprotection
operated Neuroprotection
operated Neuroprotection
operated, nitric oxide Neurodegeneration
cerol Not yet determined
oxygen species, ADP-ribose, nicotinamide adenine
de
Neurodegeneration
oxygen species Neurodegeneration
, heat (>43 °C), pH (<5.9), bradykinin, nitric oxide Neurodegeneration
TRPV1 in mice brain was determined by real-time RT-PCR. TRP subfamilies
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Enrichment of TRPC3 is reported in the CNS [20]. In this
study, the temporal and spatial distribution of TRPC3 parallels
that of the neurotrophin receptor TrkB, and activation of TrkB
by brain-derived neurotrophic factor (BDNF) leads to a TRPC3
cation influx that is dependent on PLC. Neurotrophin receptors
regulate a variety of effects in the nervous system, including
neuronal differentiation, cell proliferation, cell survival, and
modulation of neurotransmitter release at developing synapses
[44]. It is generally accepted that alterations in the structure and
function of tau protein are the primary pathology of a variety of
neurodegenerative diseases [45], although the events leading to
the deregulation of tau protein in AD are not clear. Recently,
severe disturbance of BDNF has been reported in AD [46].
Since BDNF is one of the important neurotrophic factors for the
proper functioning of neurons as described above, its alteration
can lead to the deregulation of tau protein. Interestingly,
increased [Ca2+]i leads to hyperphosphorylation of tau and
enhances vulnerability to cell death and memory-related deficits
[47]. Therefore, it can be surmised that abnormality of TRPC3
downstream of BDNF is involved in the deregulation of tau
protein in AD.
2.3. PS2 regulates Ca2+ entry via the activation of TRPC6
Mutated PS genes account for the majority of cases of
familial AD [4,5]. PSs are integral membrane proteins that are
mainly located in the ER of neurons [48,49], and act mainly as a
catalytic subunit of the γ-secretase complex [4]. Recently, it has
been shown that PSs are involved in Ca2+ signaling in neurons
[50–53]. Dysregulation of Ca2+ signaling evoked by mutations
in PS may play a role in the neurodegenerative and hallmark
pathological lesions of AD [54–56]. Elevated [Ca2+]i can
modulate the proteolytic processing of APP and thereby
increase the production of neurotoxic Aβ [57]. Thus, AD-
linked mutations in PS are implicated in the attenuation of Ca2+
entry and the augmentation of Ca2+ release from the ER in
various cell types. However, the mechanisms underlying altered
Ca2+ signaling remain unknown. A recent report demonstrates
that, in HEK293 cells, PS2 influences TRPC6-mediated Ca2+
entry [58]. In this study, wild-type PS2 and FAD-linked PS2
variants fail to affect endogenous angiotensin II (AII)-induced
Ca2+ release or AII-induced Ca2+ entry pathways in HEK cells.
In contrast, the dominant negative mutant of PS2 enhances
AII-induced Ca2+ entry, suggesting the PS2 as an endogenous
inhibitor of Ca2+ entry. Further studies reveal that the co-
expression of wild-type PS2 or FAD-linked PS2 mutants with
TRPC6 completely abrogates AII-induced Ca2+ entry through
TRPC6 but not Ca2+ release. Interestingly, despite the co-
expression of PS2 or the FAD-linked PS2 variants, 1-oleoyl-2-
acyl-sn-glycerol is still able to activate TRPC6, suggesting that
the negative regulation of TRPC6 by PS2 is not due to a
cleavage of TRPC6 by PS2. Although more extensive studies
are necessary to clarify the mechanisms whereby PS2 regulate
Ca2+ entry via TRPC6, an intriguing hypothesis is that anintermediary protein influences the AII-induced activation of
TRPC6 under the regulatory effect of PS2.
2.4. Neurodegeneration by TRPV1 activation
A neuroinflammatory process triggered by Aβ42 is central to
the neurodegenerative process [59] (see also Section 3 below).
This inflammatory process is driven by activated microglia,
astrocytes, and the induction of proinflammatory molecules and
related signaling pathways, leading to both synaptic and
neuronal damage as well as further inflammatory cell activation.
Epidemiologic evidence as well as clinical trial data suggest that
non-steroidal anti-inflammatory drug use may decrease the
incidence of AD, further supporting the role of inflammation in
AD pathogenesis [60–62]. Although the precise molecular and
cellular relationship between AD and inflammation remains
unclear, it is possible that cytokines may mediate activation of
signaling pathways, causing further inflammation and worsen-
ing neuronal injury [59].
Capsaicin-sensitive sensory neurons are nociceptive neu-
rons, which have long been considered to be involved in
aggravation of inflammation such as tissue hyperemia and
edema [63]. TRPV1 channels are activated by vanilloid and
capsaicin and are also gated at temperatures higher than 42 °C
and under acidic conditions (pH <6) [31,32,64]. Hence, it is
conceivable that activation of TRPV1 is sensitized by signaling
pathways downstream of a variety of receptors involved in
inflammation. Recent evidence has indicated a wide distribution
of TRPV1 expression in microglia, astrocytes, pericytes, and
neurons in the brain [65–67]. Therefore, it is likely that TRPV1
channels contribute to AD-related neuroinflammatory pro-
cesses. A recent study reported by Kim et al. demonstrated
that exposure of mesencephalic dopaminergic (MDA) neurons
to the TRPV1 agonist capsaicin triggered cell death [68]. This
effect was inhibited by the TRPV1 antagonists capsazepine and
iodo-resiniferatoxin, suggesting that this channel is directly
involved. TRPV1-induced neurotoxicity was accompanied by
increases in [Ca2+]i and mitochondrial damage, and these
effects were inhibited by capsazepine and an intracellular Ca2+
chelator, BAPTA-AM. Treatment of cells with capsaicin or an
endogenous ligand of TRPV1 anandamide led to an increase in
mitochondrial cytochrome c release and enhanced immunor-
eactivity to cleaved caspase-3. Furthermore, intranigral injec-
tion of capsaicin into the rat brain produced cell death through
TRPV1. Taken together, these results indicate that activation of
TRPV1 channels contribute to DA neuronal damage via Ca2+
signaling and mitochondrial disruption. Similar results were
obtained from microglia treated under similar conditions [67].
Thus, TRPV1 may be involved in AD.
3. Neurotoxic factors of AD and TRP channels
Aβ is a 40–43 amino acid peptide that accumulates in the
central nervous system plaques, which are a characteristic
feature of AD [69]. Since mutations in the APP in some cases of
familial AD lead to the overproduction of Aβ [70–74], and
since Aβ is directly toxic to cultured neuronal cells [75–77], it
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caused by aggregates of Aβ causally contribute to the
pathogenesis and progression of AD. Therefore, biochemical
mechanisms that lead to Aβ-induced neuronal cell death should
be investigated for the elucidation of AD. Several mechanisms
proposed for Aβ neurotoxicity include production of ROS such
as hydrogen peroxide (H2O2) and nitric oxide (NO) as well as
excitotoxicity with intracellular Ca2+ accumulation.
The impairment of mitochondrial metabolism has been well
documented in AD patients [78–86]. In addition, several in
vitro studies of Aβ and mitochondrial function have reported
that Aβ affects mitochondrial DNA and proteins, leading to
impairment of the electronic transport chain and ultimately, to
mitochondrial dysfunction [87–95]. Recently, Lustbader et al.
[96] have reported that Aβ-binding alcohol dehydrogenase
directly interacts with Aβ in the mitochondria of AD patients
and transgenic mice and that the interaction promotes the
leakage of ROS. The studies also suggest that Aβ-induced
oxidative stress leads to apoptotic neuronal cell death that can
be inhibited by antioxidants.
Various laboratories have shown that Aβ stimulates
microglial and astrocytic NO production [97–104]. In AD,
microglia appear to cluster around Aβ plaques [105–107].
Aβ activates CD4+ T cells, which in turn produce various
cytokines – including interferon-γ (IFN-γ) – and subsequent
microglial cell activation [101,108]. The activation of microglia
causes inducible NO synthase (iNOS)-mediated NO release
[104,109,110]. Additionally, activated microglia [111] are
known to release cytokines such as interleukin-1α and β and
tumor necrosis factor-α (TNFα) [111–113]. These cytokines
can directly induce NO production in cultured astrocytes [114].
In addition, Aβ acts synergistically with cytokines such as IFN-
γ or TNFα to induce the expression of iNOS in astrocyte cell
lines in vitro [102].
In this section, we focus on TRP channels activated by the
neurotoxic factors described above, and discuss the possibility
that neuronal cell death is triggered by Ca2+ influx via
neurotoxic factor-activated TRP channels.
3.1. Oxidative stress-induced neuronal cell death and TRPM2
TRPM2, a member of the TRPM subfamily, is expressed in
many tissues and cell types including the brain, pancreatic β-
cells, and immunocytes. TRPM2 is a Ca2+-permeable, non-
selective cation channel activated by ADP-ribose (ADPR),
nicotinamide adenine dinucleotide (NAD), ROS such as H2O2,
and the oxidant tertbutylhydroperoxide [30,115]. ADPR
activates TRPM2 by binding to the TRPM2 C-terminal
NUDT9-H domain (Nudix motif), which has homology to
NUDT9 ADPR hydrolyase but only a low level of ADPR
hydrolase activity [116–121]. While our patch-clamp studies
indicate that NAD also can directly induce opening of TRPM2
[30], this may be mediated by conversion to ADPR [116,121].
Our studies using fura-2 fluorescence to monitor [Ca2+]i
changes in intact cells, as well as patch-clamp experiments,
have shown that ROS such as H2O2 activates TRPM2 [30].
Despite consensus in the literature about this finding, thepotential gating mechanism underlying it has been subject to
some controversy and is currently unresolved. The question that
remains is whether ROS gating of TRPM2 is due to direct
activation at the membrane, or an indirect mechanism via
a diffusible second messenger such as ADPR or NAD. In-
terestingly, recent data suggest that oxidative stress induces
production of ADPR within the mitochondria, which is then
released in the cytosol to activate TRPM2 [121]. Induction
of NUDT9 ADPR pyrophosphatase, which degrades ADPR,
suppresses H2O2-induced Ca
2+ transients, providing strong
support for a requirement for ADPR binding in TRPM2 gating.
Ca2+ influx via H2O2-activated TRPM2 induces cell death in
rat insulinoma RIN-5F cells expressing TRPM2; TRPM2-
specific antisense oligonucleotide significantly suppressed Ca2+
influx and cell death induced by H2O2. TRPM2-specific
antisense almost abolished TNFα-evoked [Ca2+]i oscillation
in RIN-5F cells, as observed for omission of extracellular Ca2+,
and significantly suppressed TNFα-induced death in RIN-5F
cells [30]. The results suggest important involvement of
TRPM2 in TNFα-activated Ca2+ channels that mediate cell
death. Therefore, it is possible that TNFα released from Aβ-
activated microglia triggers neuronal cell death via TRPM2
activation in AD. In fact, TRPM2 expressed in rat cortical
neurons is critically involved in H2O2-induced Ca
2+ influx that
causes neuronal cell death [122]. Importantly, Fonfria et al.
[123] have suggested that activation of TRPM2, functionally
expressed in primary cultures of rat striatum, contributes to Aβ-
and oxidative stress-induced striatal cell death, thereby provid-
ing evidence that TRPM2 activity may contribute to neuronal
cell death in pathophysiological circumstances in which ROS
are generated abundantly.
3.2. Does Ca2+ influx via TRPM7 induce neuronal cell death?
TRPM7 functions as an ion channel but also has a C-terminal
Ser/Thr kinase domain with homology to the eEF2 α-kinase
family [124,125]. TRPM7 is widely expressed, and electro-
physiological analyses of currents in TRPM7-expressing cells
have revealed both non-selective conductance of Na+ and Ca2+
[125] and selectivity towards divalent cations [124]. Mg2+
permeability is a unique feature of TRPM7 among known ion
channels. TRPM7 currents are activated by a drop of Mg·ATP
below a certain level, and are inhibited by Mg2+ and Zn2+,
blocking monovalent cation flow [124,126]. Although a ques-
tion has been raised as to whether the TRPM7 kinase domain is
involved in regulating channel activity, recent studies have
suggested a model in which the TRPM7 kinase domain is not
required for channel activation, but have rather proposed that the
linkage between the channel and kinase domain functions to
position structures such that they can be influenced by the kinase
domain in mediating Mg2+ and Mg·ATP suppression. Several
studies have shown that TRPM7 plays a critical role in cellular
Mg2+ homeostasis and the entrance of trace metals into the cell
[127,128].Moreover, deletion of TRPM7 ultimately leads to cell
death, clearly supporting the fact that its activity is essential for
survival [124]. It has been also demonstrated that TRPM7 is
involved in cell proliferation and cell cycle progression [129].
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vitro ischemic neuronal injury, oxygen–glucose deprivation
(OGD). In this model, treatment of primary cortical neurons with
glutamate receptor antagonists prevents neuronal death when
these are exposed to OGD for up to 1 h. However, anti-
excitotoxic therapy becomes ineffective when OGD is extended
to 1.5–2 h, even in the presence of blockers of excitatory amino
acid receptors, Ca2+ channels, Na+ channels, and all ionic entry
pathways. Moreover, cell death in prolonged OGD (>1.5 h) is
associated with neuronal Ca2+ accumulation and the activation
of a cation current having the properties of a Ca2+-permeable,
non-selective cation conductance named IOGD. Both IOGD and
the neuronal Ca2+ uptake caused by prolonged OGD are blocked
pharmacologically by compounds that inhibit ROS production
through the NO/superoxide free radical pathways, suggesting
that the NO-mediated ROS signaling pathway is a key player in
activating IOGD. Depletion of TRPM7 by siRNA blocked Ca
2+
uptake and ROS-mediated activation of IOGD and, most
importantly, conferred resistance to cell death in cultured
neurons exposed to up to 3 h OGD. In the culture system,
TRPM7 gating appears to lie downstream from NMDA-
mediated NO free radical production. In this paradigm,
excitotoxicity is probably the initiating signal in a cell death
cascade that is involved in neuronal NOS activation via NMDA
receptor with subsequent peroxynitrite production, which in turn
activates TRPM7 channels. Additionally, in neurons treatedwith
sodium nitroprusside, a chemical NO donor, a steady increase in
production of ROS was observed. When TRPM7 expression
was knocked down using siRNA, the overall production of ROS
was suppressed, indicating that TRPM7, once activated by
nitrogen or oxygen free radicals, contributes to the further
production of ROS. Ca2+ influx through TRPM7 then creates a
positive feedback loop of ROS production, which eventually
kills the neuronal cell. In primary cortical neurons, knockdown
of TRPM7 also results in knockdown of TRPM2, suggesting
that the expression of these two proteins in cortical neurons is
interdependent. In our recent studies [24], although TRPM7was
activated by H2O2, H2O2-induced Ca
2+ responses of TRPM7
were very small compared to TRPM2. And NO donor activated
TRPM2 only at high concentrations, and did not activate
TRPM7. It is possible that the sensitivity of TRPM7 to ROS is
enhanced by forming heteromers with TRPM2. Considering that
TRPM7 is activated by ROS and critical for the progression of
anoxic cell death in a model of in vitro ischemic neuronal injury,
Ca2+ overload via oxidative stress-activated TRPM7 may
participate in the development of AD.
Not only Ca2+ but also Zn2+ is a potently toxic cation
involved in neuronal injury. The mechanisms by which Zn2+
exerts its neurotoxicity include mitochondrial and extra-
mitochondrial production of ROS and disruption of metabolic
enzymatic activity, ultimately leading to activation of apoptotic
and/or necrotic processes [131]. It has been suggested that
imbalances of Zn2+ may be involved in AD [132]. In fact, levels
of Zn2+ were increased in Alzheimer's subjects compared to
normal subjects [133–135]. Additionally, Bush et al. [136]
showed that Aβ specifically binds to Zn2+. Zn2+ at high
concentrations accelerates aggregation of Aβ peptide, suggest-ing a role for Zn2+ metabolism in the pathogenesis of Aβ
deposition in AD. Hermosura et al. [137] have reported the
identification of a TRPM7 variant in a subset of Guamanian
amyotrophic lateral sclerosis and parkinsonism-dementia
patients that causes a missense mutation, changing Thr-1482
to isoleucine. In functional studies, it was demonstrated that the
channel protein encoded by the variant is more sensitive to
inhibition by internal free Mg2+. They proposed the possibility
that the mutant impairs cellular ion homeostasis, which leads to
Guamanian amyotrophic lateral sclerosis and parkinsonism-
dementia. Because it is known that TRPM7 is also permeable to
Zn2+, Zn2+ homeostasis disruption induced by impairment of
TRPM7 may participate in AD.
3.3. Does NO-induced activation of TRPC5 lead to neuronal
cell death?
TRPC5 is the canonical TRP channel first cloned from the
mouse brain [23], and is known to be expressed widely in the
brain, testis, kidney, ovary, adrenal gland, uterus, and
endothelial cells. The report describes a Ca2+-permeable,
receptor-operated channel activated independently of store
depletion. Our recent study has revealed that the basal [Ca2+]i
act on calmodulin to activate myosin-light-chain kinase, and
that the phosphorylation of the myosin light chain maintains cell
surface localization of TRPC5 proteins. Thus, TRPC5 proteins
are constitutively expressed at the plasma membrane to form
channels activatable upon G-protein-coupled receptor stimula-
tion [138]. Additionally, Bezzerides et al. [139] have shown that
growth factor initiates the rapid translocation of TRPC5
channels from vesicles just under the plasma membrane to the
cell surface through the phosphatidylinositide 3-kinase path-
way. In neurons, a dominant-negative mutant of TRPC5 (DN-
TRPC5) harboring an substitution of three amino acids between
the fifth and sixth predicted transmembrane domain induces an
increased length of neurites as well as filopodia, the finger-like
projections characteristic of growth cones [22]. The results
suggest that TRPC5-mediated Ca2+ entry is an important
determinant of axonal growth and growth cone morphology.
Most recently, we have demonstrated activation of the TRPC5
channel via cysteine S-nitrosylation, and as well as a structural
motif essential for the activation gating [24]. Among TRPCs,
TRPC5 shows prominent sensitivity to NO. Our results also
suggest that NO and reactive disulfides selectively modify
Cys553 and Cys558 residues that are coupled to the gating
apparatus in functionally critical domains of the TRPC5 protein.
Because C553S and C558S mutations of TRPC5 only partially
suppress receptor-induced TRPC5 responses, the cysteines are
not absolute necessities but probably play an important
regulatory role in TRPC5 activation. Our experiments provide
further evidence for activation of native TRPC5 channels by
nitrosylation via endothelial NOS upon ATP receptor stimula-
tion in endothelial cells. Although precise identification of
physiological protein interaction between nitrosylated TRP
channels and NOSs is necessary, it can be speculated that Ca2+
influx via nitrosylated TRPC5 mediates the positive feedback
regulation of Ca2+-dependent NO production.
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Aβ stimulates microglial and astrocytic NO production, it is
possible that this NO production induces Ca2+ influx via
TRPC5 in neuronal cells. Neuronal NOS is Ca2+ dependent.
Therefore, as well in neuronal cells, Ca2+ influx via nitrosylated
TRPC5 may mediate the positive feedback regulation of Ca2+-
dependent NO production, whose disregulation may underlie
Ca2+ homeostasis disruption and neuronal cell death in AD.
Additionally, the alignment of amino acid sequences surround-
ing Cys553 and Cys558 of TRPC5 with counterpart sequences
shows that TRPC5's closest relatives, TRPC1 and TRPC4, as
well as TRPV1, TRPV3, and TRPV4, have cysteines conserved
on the N-terminal side of the putative pore-forming region.
Notably, TRPC1 and TRPC4 associated with TRPC5, and with
TRPV1, TRPV3, and TRPV4, respond well to NO. Thus, it is
conceivable these TRP channels may also be involved in Ca2+
homeostasis disruption in AD.
It was reported that 7-ketocholesterol, a component of
oxidized LDL, treatment induces an increase in [Ca2+]i in
THP-1 monocytic cells [140]. This increase was correlated
with the induction of 7-ketocholesterol-induced apoptosis,
which appeared to be associated with the dephosphorylation
of the proapoptotic protein Bcl-2 antagonist of cell death. It
was also demonstrated that Bcl-2 dephosphorylation results
mainly from the activation of Ca2+-dependent phosphatase
calcineurin via the oxysterol-induced increase in [Ca2+]i.
Moreover, the [Ca2+]i increase was likely to be mediated by
the incorporation of 7-ketocholesterol into lipid raft domains of
the plasma membrane, followed by the translocation of TRPC1
to rafts. Bezzerides et al. [139] have proposed that the channels
may be sequestered into vesicles and inserted into the plasma
membrane when and where they are needed to induce
spatiotemporally restricted Ca2+ entry through TRPC channels
and to avoid Ca2+ overload. As described above, the activation
of TRPC5 is regulated by the translocation of TRPC5 to the
plasma membrane. If the mechanism that controls TRPC5
translocation to the plasma membrane as TRPC1 is disregu-
lated, Ca2+ overload leading to AD may be triggered.
4. Conclusions
In this review, we have discussed the involvement of TRP
channels in AD. Accumulated evidence indicates that TRP
channels mediate physiological responses as multifunctional
cellular sensors. Since it is thus obvious that they are implicated
in so many fundamental cell functions, establishing their impact
on pathophysiology and disease will become an urgent priority
in biomedical sciences. Increasing knowledge regarding the
link between TRP channels and AD should lead to a fruitful
development of innovative drugs in AD.
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